Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN66,6966,71-2,47
Msft1,44
Nokia3,38053,4495-1,09
IBM-1,06
Mercedes-Benz Group AG70,6470,66-5,15
PFE6,09
02.05.2024 1:38:46
Indexy online
AD Index online
select
AD Index online
 

  • 01.05.2024
Bioporto (BIOPOR.CO, Copenhagen)
Závěr k 1.5.2024 Změna (%) Změna (DKK) Objem obchodů (DKK)
1,30 0,46 0,01 446 335
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiBioPorto A/S
TickerBIOPOR
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RICBIOPOR.CO
ISINDK0011048619
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 31
Akcie v oběhu k 31.12.2023 379 657 461
MěnaDKK
Kontaktní informace
UliceTuborg Havnevej 15, St.
MěstoHELLERUP
PSČ2900
ZeměDenmark
Kontatní osobaChristina Thomsen
Funkce kontaktní osobyInvestor Relations Manager
Telefon4 545 290 000
Fax4545290001
Kontatní telefon4 545 290 034

Business Summary: Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, BioPorto A/S revenues increased 7% to DKR31M. Net loss decreased 26% to DKR56.3M. Revenues reflect The NGAL test segment increase of 25% to DKR18.6M, North America segment increase of 17% to DKR17.5M. Lower net loss reflects Staff costs decrease of 38% to DKR18.9M (expense), Other R & D decrease of 30% to DKR12.2M (expense).
Odvětvová klasifikace
TRBC2012Laboratory Diagnostic & Testing Substances
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardJohn Mcdonough-01.01.2024
Group Chief Executive Officer, DirectorPeter Moerch Eriksen6402.04.202418.07.2013
Vice Chairman of the BoardTorben Nielsen5610.04.201410.04.2014
Chief Operation OfficerJan Kuhlmann Andersen5512.09.201612.09.2016
Executive Vice President SalesFinn Fjorder-01.10.201301.10.2013
Executive Vice President and Chief Legal OfficerGry Larsen-15.04.202415.04.2024
Chief Medical OfficerChristopher Bird-01.08.201901.08.2019